TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15940615
Drug: Infliximab 4-5
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab 4-5 mg/kg
Study: 12915643
Drug: Testosterone treatment
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone treatment (500 mg, 250 mg, and 250 mg im testosterone esters)
Study: 10834413
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart (IAsp) and Regular human insulin (HI)
Study: 12062374
Drug: Omega-3 PUFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 PUFA (1.65 g per day)
Study: 10214573
Drug: ADCON-L (Adhesion
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADCON-L (Adhesion Control in a Barrier Gel)
Study: 7890391
Drug: Bivalent formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent formulation (vibrio cholerae CVD 103‐HgR and Salmonella typhi Ty21a)
Study: 7890391
Drug: CVD 103‐HgR
Approvals — FDA: no, EMA: no, PMDA: no
Description: CVD 103‐HgR followed by two doses of killed Escherichia coli K‐12 placebo
Study: 140029
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a diuretic and rauwolfia serpentina
Study: 23348842
Drug: Kava (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kava (120 mg of kavalactones per day, titrated to 240 mg if non-response)
Study: 21753154
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg QD (n = 23)
Study: 21753154
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg TIW (n = 22)
Study: 21753154
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg QW (n = 22)
Study: 21753154
Drug: Vismodegib 150
Normalized name: vismodegib 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vismodegib 150 mg QD (loading dose for 11 days)
Study: 17003947
Drug: Bibrocathol 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bibrocathol 5% ointment
Study: 17003947
Drug: Ointment vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment vehicle (control)
Study: 15267037
Drug: Oral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral artesunate (200 mg)
Study: 15267037
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate (200 mg)
Study: 11131781
Drug: Both routes
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both routes of administration
Study: 16124423
Drug: Rectal artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rectal artesunate
Study: 29165029
Drug: Tracker-based activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracker-based activity intervention (Jawbone Up24 tracker worn for ≥5 days and completed weekly calls)
Study: 29266189
Drug: Clofarabine (CLOF)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (CLOF) 30 mg/m2/d × 5, along with cyclophosphamide (CPM), etoposide (ETOP), vincristine (VCR), and pegaspargase (experimental arm 2)
Study: 29266189
Drug: Clofarabine (CLOF)
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Clofarabine (CLOF) 20 mg/m2/d × 5 (after dose reduction due to toxicity), along with cyclophosphamide (CPM) and etoposide (ETOP)
Study: 15111756
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (radical type II or III hysterectomy and lymphonodectomy) for early stage I and IIA cervical cancer
Study: 15111756
Drug: Adjuvant postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant postoperative radiation therapy or concomitant chemoradiation
Study: 15111756
Drug: Concomitant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant chemoradiation (external beam radiotherapy with chemotherapy and brachytherapy)
Study: 9197872
Drug: Combined antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antioxidant treatment with vitamin E (800 IU/day), vitamin C (1000 mg/day), and allopurinol (200 mg/day)
Study: 9197872
Drug: Combined antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined antioxidant treatment
Study: 2988589
Drug: Enalapril 2.5
Normalized name: enalapril 2.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 2.5 mg/day
Study: 27890303
Drug: Creatine monohydrate
Normalized name: Creatine Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Creatine monohydrate 6g daily as adjunctive therapy
Study: 26595967
Drug: Magnetic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetic therapy (MT)
Study: 26595967
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HT and MT
Study: 8446441
Drug: Oral fenfluramine
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenfluramine (60 mg)/morphine infusion
Study: 8446441
Drug: Oral fenfluramine
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fenfluramine (60 mg)/saline infusion
Study: 8446441
Drug: Oral placebo/morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo/morphine infusion
Study: 8446441
Drug: Oral placebo/saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo/saline infusion
Study: 26226096
Drug: Esomeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole (20 or 40 mg/d)
Study: 22627597
Drug: 80-kVp protocol
Normalized name: Olay Professional Acne Protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80-kVp protocol with a 40% reduction in contrast agent dose and hybrid iterative reconstruction algorithm
Study: 20022087
Drug: Intravesical instillation
Normalized name: ADSTILADRIN Suspension for Intravesical Instillation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical instillation of 40 mg hyaluronic acid (HA) weekly for the first month, then monthly for 2 months.
Study: 20022087
Drug: Intravesical heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical heparin treatment.
Study: 10801243
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indinavir sulfate 800 mg every 8 hours with placebo
Study: 10801243
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg every 12 hours with placebo
Study: 1484193
Drug: High-viscosity suppository
Normalized name: Mineral Oil (high Viscosity)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-viscosity suppository formulation
Study: 1484193
Drug: Low-viscosity suppository
Normalized name: polyethylene terephthalate (intrinsic viscosity 0.40-0.70)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-viscosity suppository formulation
Study: 1484193
Drug: Oral controlled-release
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral controlled-release morphine sulfate tablets
Study: 19064965
Drug: Chemotherapy (at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (at least two cycles)
Study: 15458276
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil group (n-3 fatty acids supplement)
Study: 11340105
Drug: Oral exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral exposure to butter
Study: 9683309
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin therapy (0.625 mg conjugated estrogens plus 2.5 mg medroxyprogesterone acetate daily)
Study: 7831623
Drug: Amiloride 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 7.5 mg
Study: 3262097
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g acetazolamide (ACZ)
Study: 31340842
Drug: 4CMenB two
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB two doses (0 and 28 days or 0 and 365 days)
Study: 31340842
Drug: 4CMenB doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4CMenB doses
Study: 27316706
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine 500 mg/day for 6 months
Study: 27999775
Drug: High tidal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High tidal volume (HVT) 10 mL/kg of predicted body weight (PBW)
Study: 27999775
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (LVT) 6 mL/kg PBW
Study: 27999775
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume combined with moderate hypercapnia (LVT + HC) 6 mL/kg PBW, PaCO2 45-60 mm Hg
Study: 19407724
Drug: Levetiracetam (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levetiracetam (mean endpoint dose: 2,044.1±1,065.2 mg/day, range: 250-3,000 mg/day)
Study: 17463215
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone and 4 mg glimepiride (coadministered)
Study: 17463215
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pioglitazone and 4 mg glimepiride (fixed-dose combination)
Study: 17463215
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination vs coadministered
Study: 11876711
Drug: Eradication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eradication therapy (omeprazole 20 mg b.d., clarithromycin 250 mg b.d., tinidazole 500 mg b.d. for 7 days)
Study: 9031268
Drug: Physical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical training (30 min of bicycling daily or an equal amount of other physical activities)
Study: 7346693
Drug: Dipyridamole plus
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole plus Aspirin
Study: 31384338
Drug: Palonosetron (0.075
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron (0.075 mg IV)
Study: 21280190
Drug: Tacrolimus qd
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus qd (once-daily formulation)
Study: 21280190
Drug: Tacrolimus bid
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tacrolimus bid (twice-daily formulation)
Study: 16749
Drug: Each of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each of the 5 antacids
Study: 28667510
Drug: Ganaxolone (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ganaxolone (200, 400, and 600 mg twice daily for 6 weeks)
Study: 25649275
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment session with inert aqueous cream
Study: 25649275
Drug: Control session
Normalized name: AVOBENZONE 30 mg in 1 mL / HOMOSALATE 100 mg in 1 mL / OCTISALATE 50 mg in 1 mL / OCTOCRYLENE 60 mg in 1 mL TOPICAL LOTION [SESSION SAVERS SUNSCREEN BROAD SPECTRUM SPF 30 WATER RESISTANT]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control session with inert aqueous cream
Study: 21371717
Drug: Sequential therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential therapy (amoxicillin and omeprazole for 5 days followed by clarithromycin, tinidazole, and omeprazole for 5 days)
Study: 21371717
Drug: Standard triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard triple therapy (amoxicillin and clarithromycin plus omeprazole for 7 days followed by placebo for 3 days)
Study: 10936666
Drug: Diabetic patients
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic patients on insulin treatment
Study: 9595578
Drug: Ketorolac 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1.2 mg/kg every six hrs (Protocol A)
Study: 9595578
Drug: Ketorolac 1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 1.2 mg/kg (bolus) + 0.21 mg/kg/hr (Protocol B)
Study: 9595578
Drug: Fentanyl 1
Normalized name: fentanyl 1.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 1 gamma/kg/hr + Ketorolac 0.21 mg/kg/hr (Protocol D)
Study: 2687198
Drug: Optiray 320
Normalized name: Optiray 320
DrugBank: Ioversol (DB09134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Optiray 320 mg I/mL
Study: 2687198
Drug: Omnipaque 300
Normalized name: Omnipaque 300
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omnipaque 300 mg I/mL
Study: 12963704
Drug: FU +
Normalized name: fu ling
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU + LV (bolus FU 425 mg/m2 + LV 20 mg/m2 on days 1 to 5, repeated on day 28)
Study: 12963704
Drug: FU24h (FU
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU24h (FU 2600 mg/m2 as a 24-hour infusion)
Study: 12963704
Drug: FU24h +
Approvals — FDA: no, EMA: no, PMDA: no
Description: FU24h + LV (FU 2600 mg/m2 as a 24-hour infusion + LV 500 mg/m2)
Study: 10792163
Drug: Beta-sitosterol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-sitosterol treatment continued for 18 months (38 patients)
Study: 10792163
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy after beta-sitosterol (41 patients)
Study: 10792163
Drug: Beta-sitosterol treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-sitosterol treatment started after placebo (27 patients)
Study: 10792163
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy after placebo (18 patients)
Study: 3888239
Drug: Labetalol pretreatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol pretreatment (0.5 mg kg‐1 bolus followed by 0.1 mg kg‐1 h‐1 infusion)
Study: 29941810
Drug: Astaxanthin (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin (4 mg capsule)
Study: 22968615
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy with antibiotics and superlimf
Study: 10528604
Drug: Low-dose vasopressin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose vasopressin (VP) at 0.04 U/min
Study: 10707717
Drug: Roxatidine (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxatidine (75 mg bid)
Study: 2183710
Drug: Oral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ciprofloxacin (750 mg twice a day)
Study: 2183710
Drug: Intravenous broad-spectrum
Normalized name: Sentinel Spectrum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous broad-spectrum cephalosporin or nafcillin-aminoglycoside combination
Study: 6119933
Drug: Intramuscular narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular narcotic analgesic ketobemidone
Study: 8485789
Drug: Epidural morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural morphine (4 mg)
Study: 31689905
Drug: Educator-led daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Educator-led daily Energisers (3 brief 5-minute sessions each day)
Study: 25889322
Drug: Durolane (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durolane (3.0 ml injection at week 0)
Study: 25889322
Drug: Artz (five
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artz (five 2.5 ml injections at weeks 0, 1, 2, 3, and 4)
Study: 24917003
Drug: TAP-144-SR (6M)
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144-SR (6M) 22.5 mg subcutaneously
Study: 24917003
Drug: TAP-144-SR (6M)
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144-SR (6M) 30 mg subcutaneously
Study: 24917003
Drug: TAP-144-SR (6M)
Normalized name: leuprolide
DrugBank: Leuprolide (DB00007)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP-144-SR (6M) administered intramuscularly
Study: 15279525
Drug: Therapeutic alliance
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic alliance established early in treatment
Study: 15279525
Drug: Emotion regulation
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Emotion regulation capacity during Phase 2 exposure therapy
Study: 3281431
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose aspirin after early thrombolysis
Study: 31466119
Drug: Delgocitinib ointment
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib ointment 30 mg g-1
Study: 31466119
Drug: Delgocitinib ointment
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Delgocitinib ointment 30 mg g-1 and Vehicle ointment
Study: 28113021
Drug: Fentanyl Sublingual
Normalized name: fentanyl Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl Sublingual Tablets (100 µg)
Study: 28113021
Drug: Subcutaneous Morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Morphine (5 mg)
Study: 3522311
Drug: Ibuprofen 1800
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1800 mg
Study: 18240230
Drug: TNFalpha antagonists
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TNFalpha antagonists
Study: 18240230
Drug: No TNFalpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: No TNFalpha antagonists
Study: 12723463
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg almotriptan with 400 mg ketoconazole once daily
Study: 12723463
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg almotriptan alone
Study: 11102255
Drug: Lefradafiban 30
Normalized name: Lefradafibán
DrugBank: Lefradafiban (DB04863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefradafiban 30 mg
Study: 11102255
Drug: Lefradafiban 20
Normalized name: Lefradafibán
DrugBank: Lefradafiban (DB04863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefradafiban 20 mg
Study: 11102255
Drug: Lefradafiban 45
Normalized name: Lefradafibán
DrugBank: Lefradafiban (DB04863)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefradafiban 45 mg
Study: 11102255
Drug: Lefradafiban (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lefradafiban (all doses)
Study: 9297998
Drug: Systemic methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Systemic methotrexate (four 1.0 mg/kg doses of intramuscular methotrexate alternated with 0.1 mg/kg oral folinic acid)
Study: 7688379
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) treatment (12 IU/day x 12 days) with HMG/buserelin
Study: 7688379
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment with HMG
Study: 29330620
Drug: Resveratrol 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 500 mg
Study: 29330620
Drug: Resveratrol 40
Normalized name: RESVERATROL 400 mg / NICOTINAMIDE MONONUCLEOTIDE 500 mg / WHITE PEPPER 50 mg ORAL LOZENGE [Ascuoli]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol 40 mg
Study: 27733151
Drug: Soluble fiber
Normalized name: Soluble fiber
DrugBank: Methylcellulose (DB11228)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble fiber (10.5 g daily)
Study: 23698064
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive pills (COC) and progestin‐only pills (POP)
Study: 19061734
Drug: Cognitive-didactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-didactic treatment
Study: 19061734
Drug: Functional-experiential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional-experiential treatment
Study: 19061734
Drug: Cognitive-didactic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-didactic treatment (younger participants)
Study: 19061734
Drug: Functional-experiential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional-experiential treatment (participants older than 30 years)
Study: 19061734
Drug: Functional-experiential treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional-experiential treatment (participants with more years of education)
Study: 16181531
Drug: Quyu Xiaoban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quyu Xiaoban Capsule (QYXB) and conventional medicine
Study: 16181531
Drug: Conventional medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medicine alone
Study: 12562408
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate infusion (50 mg x kg(‐1))
Study: 8546093
Drug: Lovastatin intervention
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lovastatin intervention for coronary restenosis, specific dosage and duration not available
Study: 30380530
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid + intratympanic steroid injection (ITSI) (Control group)
Study: 30380530
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid + ITSI + Hyperbaric Oxygen Therapy (HBOT) (Study group)
Study: 30380530
Drug: Oral steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral steroid + ITSI + HBOT (Study group)
Study: 24555904
Drug: Lipotoxin (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipotoxin (80 mg liposomes and 200 U BoNT‐A)